In vitro anti-Cryptococcus activity of diphenyl diselenide alone and in combination with amphotericin B and fluconazole.
Jéssica Louise BenelliVanice Rodrigues PoesterLívia Silveira MunhozGabriel Baracy KlafkeDavid A StevensMelissa Orzechowski XavierPublished in: Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] (2021)
Cryptococcus is an encapsulated yeast that causes fungal meningitis, most commonly in HIV patients, with high mortality rates. Thus, the study of new treatment options is relevant. Antifungal activity of organoselenium compounds attributed to their pro-oxidative effect in fungal cells has been shown given that few data regarding its anti-Cryptococcus activity are available, this in vitro study was conducted with 40 clinical isolates of Cryptococcus neoformans. Diphenyl diselenide (DD) alone, and its interaction with amphotericin B or fluconazole, was tested by microdilution and checkerboard assays. All Cryptococcus neoformans were inhibited by DD in concentrations ≤ 32 μg/mL, and fungicidal concentrations were ≤ 64 μg/mL. Advantageous interaction between fluconazole occurred in 40% of the isolates, respectively. This study contributes with data of DD alone and in combination with classical drugs of choice for cryptococcosis treatment. Further studies focused on DD antifungal mechanism of action, and in vivo experiments are necessary.
Keyphrases
- candida albicans
- electronic health record
- induced apoptosis
- hiv infected
- cardiovascular disease
- oxidative stress
- risk factors
- human immunodeficiency virus
- cardiovascular events
- antiretroviral therapy
- machine learning
- coronary artery disease
- high throughput
- cell cycle arrest
- hiv testing
- deep learning
- drug induced
- saccharomyces cerevisiae